PARP inhibitors are a new area in the treatment of breast cancer

Abstract

The paper considers the use of poly(ADP-ribose)-polymerase inhibitors in therapy for breast and ovarian cancer. Particular attention is given to drugs, such as olaparib and BSI-201. It is noted that the emergence of drugs of this class, of course, holds great promise for using remedial measures and gives certain hopes for their optimization.

Keywords

• apoptosis
• poly(adp-ribose)-polymerase inhibitors
• olaparib and bsi-201